252 related articles for article (PubMed ID: 18936689)
1. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
Rabban JT; Glidden D; Kwan ML; Chen YY
Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
[TBL] [Abstract][Full Text] [Related]
2. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
3. Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review.
MacColl CE; Paré G; Salehi A; Hodgson N; Williams P
Am J Surg Pathol; 2021 Apr; 45(4):537-542. PubMed ID: 33105157
[TBL] [Abstract][Full Text] [Related]
4. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
6. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
7. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy.
Tamura N; Hasebe T; Okada N; Houjoh T; Akashi-Tanaka S; Shimizu C; Shibata T; Sasajima Y; Iwasaki M; Kinoshita T
Cancer Sci; 2009 Oct; 100(10):1823-33. PubMed ID: 19604245
[TBL] [Abstract][Full Text] [Related]
8. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
10. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
Peintinger F; Kuerer HM; McGuire SE; Bassett R; Pusztai L; Symmans WF
Br J Surg; 2008 Apr; 95(4):433-7. PubMed ID: 18161887
[TBL] [Abstract][Full Text] [Related]
11. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases.
Wasco MJ; Daignault S; Bradley D; Shah RB
Hum Pathol; 2010 Feb; 41(2):163-71. PubMed ID: 19800100
[TBL] [Abstract][Full Text] [Related]
12. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.
Cheng E; Ko D; Nguyen M; Moo TA; Andreopoulou E; Hoda SA; D'Alfonso TM
Am J Surg Pathol; 2017 Sep; 41(9):1275-1282. PubMed ID: 28654428
[TBL] [Abstract][Full Text] [Related]
13. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
Apple SK; Suthar F
Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant induction chemotherapy.
Schwartz G
Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy.
Sioshansi S; Ehdaivand S; Cramer C; Lomme MM; Price LL; Wazer DE
Cancer; 2012 Aug; 118(16):3893-8. PubMed ID: 22864932
[TBL] [Abstract][Full Text] [Related]
17. Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma.
Guilbert MC; Overmoyer B; Lester SC
Am J Surg Pathol; 2018 May; 42(5):679-686. PubMed ID: 29394169
[TBL] [Abstract][Full Text] [Related]
18. Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response.
Lee H; Jang Y; Cho YA; Cho EY
Hum Pathol; 2024 Mar; 145():1-8. PubMed ID: 38311186
[TBL] [Abstract][Full Text] [Related]
19. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
20. CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy--histological correlation.
Ogawa Y; Nishioka A; Kubota K; Kariya S; Yoshida S; Maeda H; Tanaka Y; Moriki T; Tochika N
Oncol Rep; 2003; 10(5):1411-5. PubMed ID: 12883716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]